Evidence map›Paper›PMID 39873718›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Effectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review.

Jéssyca Milene Ribeiro, Aleksander Brandão Santana, Letícia de Oliveira Marusso, Danielle Aparecida Ferreira de Oliveira Marrafon, Tiago Marques Dos Reis, Pedro Luiz Rosalen, Larissa Helena Lobo Torres, José Eduardo Tanus-Santos, Carla Speroni Ceron

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jéssyca Milene RibeiroFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0003-0068-0061
Aleksander Brandão SantanaFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0003-2132-5800
Letícia de Oliveira MarussoFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0001-8705-9117
Danielle Aparecida Ferreira de Oliveira MarrafonFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0002-1529-5919
Tiago Marques Dos ReisFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0002-0789-0187
Pedro Luiz RosalenFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0003-0812-4027
Larissa Helena Lobo TorresFaculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.ORCID 0000-0002-7065-7484
José Eduardo Tanus-SantosDepartment of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, São Paulo, Brazil.ORCID 0000-0002-9945-9633
Carla Speroni CeronDepartment of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil. carla.ceron@ufop.edu.br.ORCID 0000-0001-8882-5792

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 302076/2022-0 and 406442/2022-3Coordenação de Aperfeiçoamento de Pessoal de Nível Superior" (CAPES) 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00946-23
6 · The paper itself

Abstract

Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status. The primary outcomes analyzed were the efficacy and safety of sodium nitrite. A total of nine articles were included, eight from databases and one from gray literature. Sample sizes ranged from 5 to 36 patients, with sodium nitrite doses between 240 µg/kg/h and 325 mg. Five studies showed positive results for treating essential hypertension. Regarding safety, only one study raised concerns about adverse effects, probably due to the high dose that was used. In pulmonary hypertension patients classified as groups 2, 3, and 5, four studies suggested sodium nitrite was effective and safe, but it was ineffective in group 1. The studies included several significant limitations that should be considered. As such, the current evidence is insufficient to definitively confirm the efficacy and safety of sodium nitrite in hypertensive patients. Further research with larger sample sizes is necessary to obtain more conclusive results.

Indexed as

Antihypertensive AgentsHypertensionHypertension, PulmonarySodium NitriteHumansTreatment OutcomeAntihypertensive AgentsSodium NitriteAdverse effectsClinical outcomesQualitative synthesisTreatment effectivenessVasodilators

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.